From the literature: Adverse reactions to drugs are culprits in many deaths and injuries forchildren under 2
Adverse reactions to drugs are a significant cause of death and injuryin infants and children younger than 2 years, according to a report in theNovember issue of Pediatrics. The potential for adverse reactions in childrenis higher than it is in adults because young children have immature detoxificationmechanisms and because doses must be adjusted over a very wide range ofbody size and weight.
FDA Approves Two More Denosumab Biosimilars, Conexxence and Bomyntra
March 27th 2025The fourth pair of denosumab biosimilars, Conexxence and Bomyntra, are expected to launch in the United States in mid 2025, as a result of a global settlement with Amgen, according to a company news release.
Read More
FDA Approves First Drug for Excess Hunger in Prader-Willi Syndrome
March 27th 2025Vykat XR will be available in April to treat the intense hunger that is a hallmark of the rare genetic disease Prader-Willi syndrome. The price is based on a patient’s weight, and the average patient in the clinical trials would have had an average annual cost of $466,200 for the first year.
Read More
